Endo adds to a pileup of bad news as lead drug flunks PhII study
Endo International is adding some clinical woes today on top of its toxic pileup of opioid litigations.
The Dublin-based pharma put out word Friday that its Phase II study of collagenase clostridium histolyticum — sold as Xiaflex — failed the primary endpoint in treating adhesive capsulitis, better known as “frozen shoulder.”
We don’t have the data, but Endo said that while there was some improvement in the change from baseline in the adapted American Shoulder and Elbow Surgeons Standardized Shoulder Form composite score for the affected shoulder at the Day 95 visit, it didn’t change significantly from what the placebo arm recorded.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
